Pacira BioSciences, Inc. (PCRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Core Insights - The company has implemented a 5x30 strategy aimed at creating value, which includes reaching 3 million patients by 2030, achieving double-digit top-line growth, expanding margins by 5 points, developing 5 pipeline products, and establishing 5 partnerships [2] Group 1: Product Portfolio and Financial Performance - The company has made significant progress in the past year, particularly with the implementation of the NOPAIN reimbursement in January, which is expected to impact financial performance positively [1][3] - The first year of the NOPAIN reimbursement has provided valuable insights and learnings for the company [1]